Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just do proper due diligence.
This company has done its best to obfuscate their history and only product to cover up a horrid past and scam retail investors.
Asensus is the third name that this company is operating under. Their prior names were Transenterix and SafeStitch, both of which have never recorded a profit since inception as SafeStitch in 2005.
Each “company” has had just one product that was FDA approved under each company name and every one of them failed to generate a single dollar.
SAFESTITCH; Had a product named “SafeStitch” which was a Low Anterior Bowel Resection anastomotic device used for surgical intervention (cancer removal). It simplified the process of a purse-string suture technique that was time consuming. After FDA approval, this product was welcomed into the OR by general surgeons and did save time. Unfortunately, within months, patients were experiencing sepsis and many died due to a failure of the suture leading to anastomotic leaks.
TRANSENTERIX; Had FDA approval of their “SPYDER” RASD (Robtic Assisited Surgical Device) which proved to be cumbersome and lacking efficacy. It was shelved after a “No Sale” opinion from surgeons and hospitals. SURGIBOT; another RASD attempt that the FDA denied.
Telap-ALF X (Renamed Senhance) was created in 2003 by a nuclear research company that SOFAR thought may be viable in a OR setting. They found that it wasn’t and Todd Pope purchased the platform with shareholders money.
Asensus; Now continues with the same old product and a 3 year old employee that was promoted to CEO after Todd Pope and Joseph Slattery left the company two years ago.
Welcome Anthony Fernando, you were in charge of selling Senhance worldwide and you never registered a single commercial sale. Ever.
Go to PubMed (dot com) and research Telap ALF X and Senhance.
Just do proper due diligence.
This company has done its best to obfuscate their history and only product to cover up a horrid past and scam retail investors.
Asensus is the third name that this company is operating under. Their prior names were Transenterix and SafeStitch, both of which have never recorded a profit since inception as SafeStitch in 2005.
Each “company” has had just one product that was FDA approved under each company name and every one of them failed to generate a single dollar.
SAFESTITCH; Had a product named “SafeStitch” which was a Low Anterior Bowel Resection anastomotic device used for surgical intervention (cancer removal). It simplified the process of a purse-string suture technique that was time consuming. After FDA approval, this product was welcomed into the OR by general surgeons and did save time. Unfortunately, within months, patients were experiencing sepsis and many died due to a failure of the suture leading to anastomotic leaks.
TRANSENTERIX; Had FDA approval of their “SPYDER” RASD (Robtic Assisited Surgical Device) which proved to be cumbersome and lacking efficacy. It was shelved after a “No Sale” opinion from surgeons and hospitals. SURGIBOT; another RASD attempt that the FDA denied.
Telap-ALF X (Renamed Senhance) was created in 2003 by a nuclear research company that SOFAR thought may be viable in a OR setting. They found that it wasn’t and Todd Pope purchased the platform with shareholders money.
Asensus; Now continues with the same old product and a 3 year old employee that was promoted to CEO after Todd Pope and Joseph Slattery left the company two years ago.
Welcome Anthony Fernando, you were in charge of selling Senhance worldwide and you never registered a single commercial sale. Ever.
Go to PubMed (dot com) and research Telap ALF X and Senhance.
“ Asensus Chief Executive Anthony Fernando said the FDA clearance will allow the Senhance system to be used in high-value surgeries, such as those used to treat reflux and obesity.”
————————————————————————————————————
Those surgeries would be a laparoscopic nissen fundoplication, gastric sleeve and Roux-en-y Gastric Bypass. All of these procedures require a surgical technique called counter traction.
With only 3 arms, Senhance is incapable of counter tracting, so my question is simple.
How are you going to do it?
Then why does it convert 6% of the time while DaVinci converts less than 1%?
Making money? Lol, For the three months ended September revenue was 750K.
For the three months ended September 30, 2020, net loss attributable to common stockholders was $15.1 million, or $0.15 per share.
If you think .95 is making $$$ after a 13:1 RS? You are.
Are the uneducated still pumping this garbage?
FDA this, FDA that. Get this through your heads......
THE PLATFORM IS NOT VIABLE. This isn’t opinion, it’s based on clinical studies.
TRXC knows it, their own surgeons alluded to it as well. The only reason they’ve submitted anymore for appointments is for a pump to further fleece uneducated retail investors.
Wrong again. I told you at $6.50 this was EXACTLY what was going to happen. ??
Easy money. Right Trader? ????
It only took Pope 7 years to admit it.
Can you hear me now? Just linked I called it since $6.50. FO to all those that tried doing damage.
At least Spider and Surgiflop will have companion the shelf. 3 three stooges.
I predicted sub buck;)
After (lack of) earnings, it’s gonna happen.
I’ll cover at .79
Making good money since SafeStitch? Lol!
They were sued for that due to anastomotic leaks and the FDA yanked it! Just another Pope fail.
They’ll be worth 0
In just a few months.
LOL, Pope is now selling assets again!
Rumor has it that a new article is in the making and due out soon and it ain’t pretty!
Can you hear me now?
Um, no. It’s not a new upgrade, it’s the same platform that was designed in 2009 les the 4th arm due to the massive footprint.
The 4th gen Xi was approved in late 2014 and has been in use for just over 4 years, the Davinci X was approved in 2017 and costs $130K less than Alf. The Davinci SP was just approved last year.
Welcome to index funds. Why are you excited? The CEO and CFO have sold hand over fist. The platform is 20 years old and can’t perform basic counter traction.
Not one “sale” to date has been commercial.
As a RASD technician, I think SPORT has a shot.
It’ll be the first on to challenge Davinci but Intuitive has a footprint.
I’d play the FDA “approval” then sell into it.
At least TMDI has a viable platform. Watch out for VERB though. As for Transenterix and “ALF”...... toast and feeling sorry for the Pope scammed investors.
Hilarious! No, “everything “ didn’t come out in the “same manner”. Intuitive’s platform was initially designed for surgical procedures, Alf wasn’t.
Intuitive was created for the design of a surgical RASD.
Transenterix has been attempting to sell ANYTHING and has never made a profit. They actually incurred a billion dollar lawsuit for a device that was FDA “approved” and 6 months later failed on several surgeries involving low anterior anastomotic fixation. That led to patient deaths around the country, the FDA yanked it. (Just like they yanked Alf’s 4th arm for taking up the entire OR suite). ALF was never intended to be a RASD but Pope punked you anyway.
And Transenterix is down even more.
Yes they were. I’d say 2-4 more lawsuits are coming within a weeks or so.
I told everyone to sell at $6.50 for a simple reason in 2015 and 2017.
I do RASD for a living and I knew that the renamed TelapALF-X was a scam.
Todd Pope scammed retail investors while EVERY SINGLE PICE OF DATA proved “Senhance” was a non viable platform.
Todd Pope had this information long before he lied to retail investors.
Telap ALF-X. AKA “Senhance” was never designed to be a surgical Robotic device. It was first built in 2003
https://ec.europa.eu/jrc/en/news/nuclear-research-surgery-technology
From nuclear research to surgery technology
From nuclear research to surgery technology
ec.europa.eu
LMAO at STOCKTWITS! Those administrators dot know shot from a shingle! They’re complicit in stock fraud
Pope scammed you! I warned you I 2015. You LOST.
Thank god that someone else knows it!
Pope explains ALF. HILARIOUS!
I wanted to refute every statement he made but after 9 minutes, that ass clown couldn’t even get two sentences out before I called BULLSHIT!
I couldn’t even stop laughing.
Anyway.. here’s it is...
My rebutal is in the comments .
Keep holding. What you just said is that you got in a $1.90 and rode it to $6.70 without selling a 350% profit on a scam.
Now it at 2.50.
Hilarious!
Mic Drop!
It take no balls to short a company when you KNOW the product isn’t viable.
Transenterix was a guaranteed short to those with surgical know how.
Hilarious! Unless you’re short the stock
CMR will challenge.
Transenterix will be BK in 1 year.
https://cmrsurgical.com/versius/
Telap ALF-X. AKA “Senhance” was never designed to be a surgical Robotic device.
https://ec.europa.eu/jrc/en/news/nuclear-research-surgery-technology
From nuclear research to surgery technology
From nuclear research to surgery technology
ec.europa.eu
I’ve been preaching that since 2015. Pumpers on this stock have cost retail investors big time.